Amylin, Lilly and Alkermes Receive Complete Response Letter from FDA for exenatide Once Weekly Submission
SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.—-Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ .

Read more on Business Wire via Yahoo! Finance